BCL
CRXT

Bracebridge Capital LLC’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Bracebridge Capital LLC’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,002,495
Closed -$761K – 105
2022
Q2 		$761K Hold
2,002,495
– – 0.12% 78
2022
Q1 		$2.98M Hold
2,002,495
– – 0.22% 40
2021
Q4 		$4.87M Hold
2,002,495
– – 0.3% 30
2021
Q3 		$10.7M Buy
+2,002,495
New +$18M 0.94% 11

Other funds holding CRXT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Bracebridge Capital LLC's CRXT Position: Q3 2022 in Review

Bracebridge Capital LLC sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 2,002,495 shares — an estimated $761K sold.

Bracebridge Capital LLC first reported a position in CRXT in Q3 2021 and held it in 4 quarters. The position peaked at $10.7M in Q3 2021. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

  • Bracebridge Capital LLC reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Bracebridge Capital LLC sold 2,002,495 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $761K.
  • Bracebridge Capital LLC first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • Bracebridge Capital LLC's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $10.7M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Bracebridge Capital LLC's 13F filing for Q3 2022, filed 1 Nov 2022.